Featured Research

from universities, journals, and other organizations

Antiviral Drug Works By Causing "Genetic Meltdown"

Date:
December 11, 2000
Source:
Howard Hughes Medical Institute
Summary:
The antiviral drug ribavirin works by creating such extreme mutation rates in viruses that it drives them into "genetic meltdown," according to researchers. Uncovering the mechanism by which ribavirin disables viruses offers researchers information that can be used to design more effective antiviral drugs.

December 7, 2000 — The antiviral drug ribavirin works by creating such extreme mutation rates in viruses that it drives them into "genetic meltdown," according to researchers. Uncovering the mechanism by which ribavirin disables viruses offers researchers information that can be used to design more effective antiviral drugs.

Related Articles


Ribavirin's mutagenic mechanism was reported in the December 2000 issue of Nature Medicine by a research team that included lead author Shane Crotty, who is a Howard Hughes Medical Institute predoctoral fellow at the University of California, San Francisco (UCSF), Craig Cameron at Pennsylvania State University and scientists from Schering-Plough Research Institute.

"Ribavirin is one of the few drugs that shows activity against a variety of RNA viruses," said Crotty. These viruses use RNA rather than DNA as their genetic material. Ribavirin is used to treat severe cases of respiratory syncytial viruses in children, lassa fever and hepatitis C infections, where it is used in combination with interferon-alpha.

"Unfortunately, only about thirty to forty percent of hepatitis C patients respond to the treatment," said Crotty. "Once people are chronically infected, they don’t appear to get rid of the virus and there is a high incidence of liver failure in these patients. Nevertheless, ribavirin plus interferon-alpha is the closest we’ve gotten to a cure right now," he said.

Thus, said Crotty, there is a great deal of interest among pharmaceutical companies in understanding ribavirin's mechanism of action. Researchers have suggested several theories about how ribavirin works, including speculation that ribavirin blocks viral protein synthesis or that it halts the transcription of RNA needed for viral replication.

To determine whether ribavirin does, indeed, interfere with RNA transcription, Cameron and his colleagues used a sensitive analytical assay to see whether ribavirin is incorporated into viral RNA. Those experiments revealed that a form of the drug called ribavirin triphosphate (RTP) is incorporated into viral RNA. RTP resembles the nucleotide building blocks that normally make up RNA.

"This finding was reasonable to expect because other antiviral drugs that resemble nucleotides are also incorporated into the viral genetic material, acting as chain terminators to block further RNA elongation," said Crotty. "However, what was confusing was that Cameron's experiments also showed that ribavirin was not a chain terminator because RNA translation continued," he said.

To understand how ribavirin affects viruses in vivo, Crotty, working in the laboratory of Raul Andino at UCSF, tested the drug's effect on live poliovirus using an assay he had developed to determine the level of mutation in poliovirus. Crotty's assay measured how frequently poliovirus in culture mutates to develop resistance to the molecule guanidine, both in the absence and in the presence of ribavirin. Crotty's measurements revealed that ribavirin increased the mutation rate of the poliovirus cultures by a large amount.

"Normally, a high rate of mutation is a survival trait used by viruses such as HIV, influenza and poliovirus to escape the immune system or to develop resistance to antiviral drugs," explained Crotty. "Importantly, data from other researchers studying poliovirus have indicated that the virus is mutating as much as it possibly can, and if it mutates any more, it starts dying. Its genetic information is degraded so much that it doesn't make sense.

"My experiments convinced me that ribavirin is pushing poliovirus into what's called an 'error catastrophe'—in other words, a genetic meltdown," said Crotty.

Evidence that ribavirin pushes viruses to mutate suggests that the apparent failure of clinical trials of ribavirin used alone against hepatitis C virus might not have been real failures, said Crotty. "Nobody knows how to grow hepatitis C in culture, so there is no assay to determine how much viable virus is left after treatment with ribavirin," said Crotty. "So, to indicate clinical effectiveness, those studies measured the blood levels of viral RNA. My data suggest that while viral RNA is present in the blood, it might be mutated to the point where it is useless."

Of broader importance, said Crotty, is that this discovery offers hope that pharmaceutical companies may be able to develop improved versions of ribavirin or completely new nucleotide mimics that can also be incorporated into the viral RNA to induce lethal genetic meltdown in RNA viruses.


Story Source:

The above story is based on materials provided by Howard Hughes Medical Institute. Note: Materials may be edited for content and length.


Cite This Page:

Howard Hughes Medical Institute. "Antiviral Drug Works By Causing "Genetic Meltdown"." ScienceDaily. ScienceDaily, 11 December 2000. <www.sciencedaily.com/releases/2000/12/001208073913.htm>.
Howard Hughes Medical Institute. (2000, December 11). Antiviral Drug Works By Causing "Genetic Meltdown". ScienceDaily. Retrieved January 29, 2015 from www.sciencedaily.com/releases/2000/12/001208073913.htm
Howard Hughes Medical Institute. "Antiviral Drug Works By Causing "Genetic Meltdown"." ScienceDaily. www.sciencedaily.com/releases/2000/12/001208073913.htm (accessed January 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, January 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Malnutrition on the Rise as Violence Flares in C. Africa

Malnutrition on the Rise as Violence Flares in C. Africa

AFP (Jan. 28, 2015) Violence can flare up at any moment in Bambari with only a bridge separating Muslims and Christians. Malnutrition is on the rise and lack of water means simple cooking fires threaten to destroy makeshift camps where people are living. Duration: 00:40 Video provided by AFP
Powered by NewsLook.com
Poultry Culled in Taiwan to Thwart Bird Flu

Poultry Culled in Taiwan to Thwart Bird Flu

Reuters - News Video Online (Jan. 28, 2015) Taiwan culls over a million poultry in efforts to halt various strains of avian flu. Julie Noce reports. Video provided by Reuters
Powered by NewsLook.com
Media Criticizing Parents For Not Vaccinating Children

Media Criticizing Parents For Not Vaccinating Children

Newsy (Jan. 28, 2015) As the Disneyland measles outbreak continues to spread, the media says parents who choose not to vaccinate their children are part of the cause. Video provided by Newsy
Powered by NewsLook.com
Shark Bite Victim Making Amazing Recovery

Shark Bite Victim Making Amazing Recovery

AP (Jan. 27, 2015) A Texas woman who lost more than five pounds of flesh to a shark in the Bahamas earlier this month could be released from a Florida hospital soon. Experts believe she was bitten by a bull shark while snorkeling. (Jan. 27) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins